From the Research
The recommended dosage of Desidustat is 100 mg oral tablets thrice a week for 24 weeks, as shown in the DREAM-ND study 1. This dosage has been found to be non-inferior to darbepoetin in the treatment of anemia due to non-dialysis dependent chronic kidney disease, with a significant increase in hemoglobin levels and a well-tolerated safety profile. The exact dosage may depend on the patient's condition, hemoglobin levels, and response to treatment, but 100 mg thrice a week is the established dosage based on the most recent and highest quality study available 1. Some key points to consider when prescribing Desidustat include:
- The medication should be taken orally, with or without food, at approximately the same time each day
- Dose adjustments may be necessary for patients with hepatic impairment
- Regular monitoring of hemoglobin levels is essential during treatment
- Desidustat works as a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), stimulating erythropoiesis by mimicking the body's natural response to hypoxia
- The full therapeutic effect may take several weeks to develop, and patients should report any unusual symptoms or side effects to their healthcare provider immediately. It's also worth noting that other studies, such as the DREAM-D study 2, have also investigated the efficacy and safety of Desidustat in patients with dialysis-dependent chronic kidney disease, but the DREAM-ND study 1 provides the most relevant and up-to-date information on the recommended dosage.